Patents by Inventor Hans-Peter Buchstaller

Hans-Peter Buchstaller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100256137
    Abstract: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: May 23, 2008
    Publication date: October 7, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Hans Peter Buchstaller, Hans Michael Eggenweiler, Christian Sirrenberg
  • Publication number: 20100234324
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: June 16, 2008
    Publication date: September 16, 2010
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Publication number: 20100160352
    Abstract: Novel adenine derivatives of the formula (I), in which R1, R2, R3, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: July 20, 2006
    Publication date: June 24, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Hans-Michael Eggenweiler, Bertram Cezanne, Michael Wolf
  • Publication number: 20100113542
    Abstract: 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: December 11, 2007
    Publication date: May 6, 2010
    Applicant: Merck Patent Gesellschaft
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Hans Peter Buchstaller, Christian Sirrenberg
  • Patent number: 7691870
    Abstract: The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Frank Zenke, Christiane Amendt, Matthias Grell, Christian Sirrenberg
  • Patent number: 7691886
    Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Matthias Wiesner, Lars Thore Burgdorf, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Publication number: 20100022540
    Abstract: Novel triazole derivatives of the formula (I) in which R1—R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: April 20, 2007
    Publication date: January 28, 2010
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Hans-Peter Buchstaller, Christian Sirrenberg
  • Publication number: 20090325974
    Abstract: Novel 1,5-diphenylpyrazole derivatives of the formula (I) in which R1-R6 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: April 20, 2007
    Publication date: December 31, 2009
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Hans-Peter Buchstaller, Christian Sirrenberg
  • Publication number: 20090298885
    Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 3, 2009
    Applicant: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
  • Publication number: 20090253688
    Abstract: The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: February 14, 2005
    Publication date: October 8, 2009
    Applicant: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Frank Stieber, Matthias Wiesner, Christiane Amendt, Christian Sirrenberg, Frank Zenke, Matthias Grell
  • Patent number: 7598274
    Abstract: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: October 6, 2009
    Assignee: Merck Patent GmbH
    Inventors: Dirk Finsinger, Hans-Peter Buchstaller, Lars Burgdorf, Matthias Wiesner, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Patent number: 7589112
    Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: September 15, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
  • Publication number: 20090215799
    Abstract: The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: October 6, 2005
    Publication date: August 27, 2009
    Inventors: Frank Stieber, Alfred Jonczyk, Guenter Hoelzemann, Hans-Peter Buchstaller, Lars Thore Burgdorf, Wilfried Rautenberg, Hartmut Greiner
  • Publication number: 20090197882
    Abstract: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: June 18, 2007
    Publication date: August 6, 2009
    Inventors: Hans Peter Buchstaller, Hans-Michael Eggenweiler, Michael Wolf, Christian Sirrenberg
  • Publication number: 20090163556
    Abstract: The present invention relates to glycinamide derivatives of formula I, A-D-B??(I), wherein A, D, and B are as herein defined, as well as the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition, and a method of treatment comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: November 18, 2008
    Publication date: June 25, 2009
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
  • Publication number: 20090118267
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: February 13, 2006
    Publication date: May 7, 2009
    Inventors: Dirk Finsinger, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Publication number: 20090082404
    Abstract: Novel compounds of the formula I in which R1, R1?, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated in Claim 1 and are, for example, inhibitors of tyrosine kinases, for example TIE-2, and can be employed, for example, for the treatment of tumours or other diseases.
    Type: Application
    Filed: December 4, 2008
    Publication date: March 26, 2009
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang STAEHLE, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg
  • Publication number: 20090030028
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Application
    Filed: June 3, 2005
    Publication date: January 29, 2009
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Patent number: 7476683
    Abstract: The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 13, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
  • Patent number: 7470702
    Abstract: Novel compounds of the formula I in which R1, R1?, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated. Further, the compounds of formula I can be used as, for example, inhibitors of tyrosine kinases, for example TIE-2 , and can be employed, for example, for the treatment of tumours or other diseases.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: December 30, 2008
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg